Genaera Corporation
news top
Press Room
  • Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust
    June 12th, 2009
  • Genaera Receives Non-Compliance Notice from Nasdaq
    May 27th, 2009
  • Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
    April 28th, 2009
  • Genaera Corporation Implements Cash Conservation Plan
    March 30th, 2009
Events
 

On June 12, 2009, Genaera Corporation transferred all of its assets and liabilities to the Genaera Liquidating Trust in accordance with the Plan of Complete Liquidation and Dissolution adopted at a Special Meeting of Stockholders on June 4, 2009. Details of the Plan of Dissolution as described in the proxy for the Special Meeting and a copy of the Liquidating Trust may be found in the Company filings section of the SEC website at www.sec.gov.

Creditors, vendors and other persons having business with Genaera Corporation should contact the Trustee at trustee@genaera.com.

Alternatively they may leave a voice mail at 610-941-4015 or send faxes 610-941-5399.

Click here to view The Genaera Liquidating Trust FAQ's

Development Pipeline - Core Assests
  • Trodusquemine (MSI-1436)
  • MEDI-528 (Anti-IL-9)

  • MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of type 2 diabetes and obesity. Genaera initiated its first-in-man clinical studies in 2Q07.
  • MEDI-528 the second core asset out-licensed to Astra Zeneca/MedImmune is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.

Genaera Corporation
5110 Campus Drive
Plymouth Meeting, PA 19462
(610) 941-4020

©2009 Genaera Corporation Inc.

Site Designed and Programmed by: Wiseacre Design